Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | IMpassion130: Implications

Peter Schmid • 3 Jun 2019
ASCO 2019
Breast Cancer Atezolizumab Paclitaxel

Peter Schmid, MD, PhD, FRCP, of the Barts Cancer Institute, London, UK, discusses the implications of the results gleaned form the IMpassion130 trial (NCT02425891). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Peter Schmid

4:20
KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
Peter Schmid • 22 Oct 2023
3:22
BEGONIA: datopotamab deruxtecan and durvalumab in metastatic triple-negative breast cancer
Peter Schmid • 22 Oct 2023
3:07
Highlights from SABCS 2021: T-DXd, KEYNOTE-355, PADA-1 & EMERALD
Peter Schmid • 9 Dec 2021
1:30
BEGONIA: durvalumab combinations in advanced TNBC
Peter Schmid • 9 Dec 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals